Email updates

Keep up to date with the latest news and content from Orphanet Journal of Rare Diseases and BioMed Central.

This article is part of the supplement: 6th European Conference on Rare Diseases and Orphan Products

Open Access Meeting abstract

Fighting for the cures of rare genetic diseases: worthy ideas and promising results demand for strategic research management and for integration of competences and efforts

Francesca Sofia

Author Affiliations

Fondazione Telethon, Milan, Piazza Cavour 1, 20100, Italy

Orphanet Journal of Rare Diseases 2012, 7(Suppl 2):A21  doi:10.1186/1750-1172-7-S2-A21


The electronic version of this article is the complete one and can be found online at: http://www.ojrd.com/content/7/S2/A21


Published:22 November 2012

© 2012 Sofia; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Meeting abstract

The fight against genetic diseases, whose aim is the amelioration of the quality and prospect of life of the patients, poses enormous challenges due to several well-known issues such as the rarity of the diseases, the scarcity of financial resources and the lack of knowledge/interest from major stakeholders of the healthcare sector. To cope with this complex and multifaceted problem, in 1990 a patient association in Italy (UILDM) founded Telethon whose mission is to advance scientific research on muscular dystrophy and all other genetic diseases with the ultimate goal of paving the way for the cures. To this end, Telethon has set an articulated strategy whose pillars are: strategic funding of science, selection of the most promising and worthy research ideas, efficient management of funded projects and exploitation of research results. Indeed, in 22 years of activity, Telethon has invested about 354 million Euros, funding 2,375 projects on more than 450 genetic diseases. Notably, Telethon research spans all steps of the research path from the most basic and preliminary phases to the clinical translation, and is increasing our understanding of many genetic diseases, as demonstrated by a wealth of high impact publications. Moreover, clinical trials for different diseases are on-going or in the process to start.

This strategy has demonstrated itself as effective in advancing biomedical research; nonetheless, it is clear that the completion of the path to make therapies available to the patients requires resources and expertise that are beyond Telethon’s capacity and that typically reside within the competence of the pharmaceutical industry. This awareness has recently led Telethon to sign an agreement with a major pharmaceutical company that will allow gene therapies, performed at the San Raffaele-Telethon Institute for Gene Therapy, to enter the last phases of the developmental process for seven different genetic diseases.

The success of this agreement set the course of what is acclaimed as “collaborative model” in the field of rare diseases.

To date, there are several basic or pre-clinical research projects in Telethon’s portfolio that constitute a reservoir of ideas and knowledge on many different genetic diseases and deserve exploitation. In this perspective, partnerships with pharmaceutical industries and with other stakeholders will not only lead to the completion of the path for the most advanced research projects but also free-up resources to be invested in research activities at earlier stages of development, thus feeding a virtuous circle.